



**ASX & MEDIA RELEASE
3 JANUARY 2012**

MARSHALL EDWARDS ISSUED NEW METHOD OF USE PATENT FOR LEAD ONCOLOGY DRUG CANDIDATE ME-344

Novogen Limited's subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following announcement.

San Diego— 3 January, 2012 – Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the US Patent and Trademark Office has issued a new method of use patent, US Patent No. 8,084,628, covering a number of the company's mitochondrial inhibitor compounds, including lead drug candidate ME-344, for the treatment of cancer or a tumour mass. The patent is expected to provide protection until September, 2025.

Treatment of tumour cells with the company's mitochondrial inhibitor compounds induces a rapid loss of cellular energy and leads to the inhibition of both mammalian target of rapamycin (mTOR1 and mTOR2) pathways. The company has completed the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug (IND) application for ME-344 this quarter, and expects to initiate a Phase I clinical trial of intravenous ME-344 shortly thereafter.

"Given the increased interest in oncology compounds that can impact both the mTOR1 and mTOR2 pathways, we are particularly pleased to receive patent coverage for the use of ME-344 in cancer," said Daniel P Gold, PhD, President and Chief Executive Officer of Marshall Edwards. "This new patent reaffirms our ongoing commitment to expanding and strengthening our intellectual property portfolio while adding to the value of our drug development pipeline. A strong patent estate is essential to the commercial potential of our drug candidates and should be recognised by potential partners."

About Marshall Edwards

Marshall Edwards, Inc., is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The company's lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The company initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumours in September, 2011 and expects final data from the trial by the second quarter of 2012. The second program is a family of mitochondrial inhibitors that includes lead candidate ME-344. The company has completed the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug (IND) application for ME-344 in the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

About Novogen Limited

Novogen Limited (ASX: NRT Nasdaq: NVGN) is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION :	:	PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE COMMUNICATIONS, MARSHALL EDWARDS, INC. TEL +1 858-792-3729 http://www.marshalledwardsinc.com
ISSUED BY CONTACT	: :	WESTBROOK COMMUNICATIONS IAN WESTBROOK TEL (02) 9231 0922



**ASX & MEDIA RELEASE
3 JANUARY 2012**

MARSHALL EDWARDS ISSUED NEW METHOD OF USE PATENT FOR LEAD ONCOLOGY DRUG CANDIDATE ME-344

Novogen Limited's subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following announcement.

San Diego— 3 January, 2012 – Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the US Patent and Trademark Office has issued a new method of use patent, US Patent No. 8,084,628, covering a number of the company's mitochondrial inhibitor compounds, including lead drug candidate ME-344, for the treatment of cancer or a tumour mass. The patent is expected to provide protection until September, 2025.

Treatment of tumour cells with the company's mitochondrial inhibitor compounds induces a rapid loss of cellular energy and leads to the inhibition of both mammalian target of rapamycin (mTOR1 and mTOR2) pathways. The company has completed the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug (IND) application for ME-344 this quarter, and expects to initiate a Phase I clinical trial of intravenous ME-344 shortly thereafter.

"Given the increased interest in oncology compounds that can impact both the mTOR1 and mTOR2 pathways, we are particularly pleased to receive patent coverage for the use of ME-344 in cancer," said Daniel P Gold, PhD, President and Chief Executive Officer of Marshall Edwards. "This new patent reaffirms our ongoing commitment to expanding and strengthening our intellectual property portfolio while adding to the value of our drug development pipeline. A strong patent estate is essential to the commercial potential of our drug candidates and should be recognised by potential partners."

About Marshall Edwards

Marshall Edwards, Inc., is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The company's lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The company initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumours in September, 2011 and expects final data from the trial by the second quarter of 2012. The second program is a family of mitochondrial inhibitors that includes lead candidate ME-344. The company has completed the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug (IND) application for ME-344 in the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

About Novogen Limited

Novogen Limited (ASX: NRT Nasdaq: NVGN) is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION :	:	PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE COMMUNICATIONS, MARSHALL EDWARDS, INC. TEL +1 858-792-3729 http://www.marshalledwardsinc.com
ISSUED BY CONTACT	: :	WESTBROOK COMMUNICATIONS IAN WESTBROOK TEL (02) 9231 0922